lamotrigine has been researched along with Absence Seizure Disorder in 70 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the efficacy and safety of long-term lamotrigine (LTG) monotherapy in Japanese and South Korean pediatric patients with newly diagnosed typical absence seizures." | 9.27 | Long-term efficacy and safety of lamotrigine monotherapy in Japanese and South Korean pediatric patients with newly diagnosed typical absence seizures: An open-label extension study. ( Kurata, A; Numachi, Y; Ohtsuka, Y; Sato, K; Shimizu, M; Yasumoto, S, 2018) |
| "To review the evidence for the effects of ethosuximide, valproate and lamotrigine as treatments for children and adolescents with absence seizures (AS), when compared with placebo or each other." | 9.12 | Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. ( Brigo, F; Igwe, SC; Lattanzi, S, 2021) |
| "This systematic review and meta-analysis of randomized controlled trials (RCTs) systematically explored the effectiveness and safety of lamotrigine for absence seizures in children and adolescents." | 9.05 | The efficacy and safety of lamotrigine for absence seizures in children and adolescents: A systematic review and meta-analysis. ( Cao, J; Lin, XX; Liu, H; Ma, XM, 2020) |
| " Lamotrigine (LTG) is an effective clinical treatment for epilepsy associated with absence seizures." | 7.78 | Lamotrigine ameliorates seizures and psychiatric comorbidity in a rat model of spontaneous absence epilepsy. ( Chen, SD; Huang, HY; Lee, HW; Shaw, FZ, 2012) |
| "In a trial including 38 children, lamotrigine, which had to be introduced very gradually in order to reduce the risk of potentially severe skin reactions, took longer than valproic acid to control typical absence seizures." | 7.75 | Lamotrigine and absence seizures: new indication. Try valproic acid first. ( , 2009) |
| "We report on the aggravation of absence seizures by lamotrigine leading to absence status epilepticus in a child." | 7.73 | Recurrent absence status epilepticus (spike-and-wave stupor) associated with lamotrigine therapy. ( Hasan, M; Lerman-Sagie, T; Lev, D; Watemberg, N, 2006) |
| "An 8-year-old girl with Lennox-Gastaut syndrome showed a partial reduction in seizure frequency when lamotrigine (LTG), 15 mg/kg per day, was added to clobazam (CLB) and vigabatrin (VGB)." | 7.70 | Myoclonic status epilepticus following high-dosage lamotrigine therapy. ( Belmonte, A; Guerrini, R; Parmeggiani, L; Perucca, E, 1999) |
| "Vigabatrin is a specific and irreversible inhibitor of the enzyme gamma-amino-butyric-acid (GABA) transferase." | 6.39 | [Vigabatrin and lamotrigin: experiences with 2 new anticonvulsants in the Swiss epilepsy clinic]. ( Krämer, G; Vogt, H, 1995) |
| "The syndrome is characterized by mental impairment, frequent seizures of multiple types that are particularly resistant to treatment, and high rates of seizure-related injury." | 5.36 | The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK. ( Benedict, A; Maclaine, G; Verdian, L, 2010) |
| "To investigate the efficacy and safety of long-term lamotrigine (LTG) monotherapy in Japanese and South Korean pediatric patients with newly diagnosed typical absence seizures." | 5.27 | Long-term efficacy and safety of lamotrigine monotherapy in Japanese and South Korean pediatric patients with newly diagnosed typical absence seizures: An open-label extension study. ( Kurata, A; Numachi, Y; Ohtsuka, Y; Sato, K; Shimizu, M; Yasumoto, S, 2018) |
| "To explore the efficacy and safety of the combined therapy of valproic acid (VPA) and lamotrigine (LTG) for various types of epilepsy." | 5.16 | [Efficacy and safety of the combined therapy of valproic acid and lamotrigine for epileptics]. ( Hu, Q; Kang, HC; Li, X; Liu, XY; Liu, ZG; Wang, M; Xu, F; Zeng, Z; Zhu, SQ, 2012) |
| "To review the evidence for the effects of ethosuximide, valproate and lamotrigine as treatments for children and adolescents with absence seizures (AS), when compared with placebo or each other." | 5.12 | Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. ( Brigo, F; Igwe, SC; Lattanzi, S, 2021) |
| "This systematic review and meta-analysis of randomized controlled trials (RCTs) systematically explored the effectiveness and safety of lamotrigine for absence seizures in children and adolescents." | 5.05 | The efficacy and safety of lamotrigine for absence seizures in children and adolescents: A systematic review and meta-analysis. ( Cao, J; Lin, XX; Liu, H; Ma, XM, 2020) |
| " The treatment of choice for CAE with absence seizures only is ethosuximide." | 5.01 | A Practical Guide to Treatment of Childhood Absence Epilepsy. ( Kessler, SK; McGinnis, E, 2019) |
| " The point estimates of carbamazepine and lamotrigine efficacy showed their superiority with respect to all comparator antiepileptic drugs for the treatment of newly diagnosed focal epilepsy." | 4.98 | Comparative efficacy of antiepileptic drugs in children and adolescents: A network meta-analysis. ( Crescioli, G; De Masi, S; Guerrini, R; Ilvento, L; Lucenteforte, E; McGreevy, KS; Mugelli, A; Pugi, A; Rosati, A; Virgili, G, 2018) |
| " Lamotrigine (LTG) is an effective clinical treatment for epilepsy associated with absence seizures." | 3.78 | Lamotrigine ameliorates seizures and psychiatric comorbidity in a rat model of spontaneous absence epilepsy. ( Chen, SD; Huang, HY; Lee, HW; Shaw, FZ, 2012) |
| "In a trial including 38 children, lamotrigine, which had to be introduced very gradually in order to reduce the risk of potentially severe skin reactions, took longer than valproic acid to control typical absence seizures." | 3.75 | Lamotrigine and absence seizures: new indication. Try valproic acid first. ( , 2009) |
| "We report on the aggravation of absence seizures by lamotrigine leading to absence status epilepticus in a child." | 3.73 | Recurrent absence status epilepticus (spike-and-wave stupor) associated with lamotrigine therapy. ( Hasan, M; Lerman-Sagie, T; Lev, D; Watemberg, N, 2006) |
| "Reversible neurotoxic symptoms were observed in three adult patients with absence status epilepticus on lamotrigine (LTG) therapy after administration of an IV bolus followed by oral valproic acid (VPA)." | 3.72 | Neurotoxicity following addition of intravenous valproate to lamotrigine therapy. ( Burneo, JG; Faught, E; Knowlton, RC; Kuzniecky, RI; Lawn, N; Limdi, N; Mendez, M; Prasad, A; Welty, TE, 2003) |
| "An 8-year-old boy developed tremor, unsteadiness, chorea, and eye movement abnormalities on starting lamotrigine for myoclonic jerks." | 3.72 | Unusual side effects of lamotrigine therapy. ( Cross, JH; Das, KB; Harris, C; Smyth, DP, 2003) |
| "We studied an eleven year-old girl with atypical, benign partial epilepsy who acutely presented a severe aphasia associated with marked EEG deterioration after lamotrigine administration." | 3.71 | Reversible aphasic disorder induced by lamotrigine in atypical benign childhood epilepsy. ( Acquafondata, C; Battaglia, D; Chiricozzi, F; Guzzetta, F; Iuvone, L; Lettori, D; Mittica, A; Pane, M; Stefanini, MC, 2001) |
| "An 8-year-old girl with Lennox-Gastaut syndrome showed a partial reduction in seizure frequency when lamotrigine (LTG), 15 mg/kg per day, was added to clobazam (CLB) and vigabatrin (VGB)." | 3.70 | Myoclonic status epilepticus following high-dosage lamotrigine therapy. ( Belmonte, A; Guerrini, R; Parmeggiani, L; Perucca, E, 1999) |
| "Childhood absence epilepsy was diagnosed based on the presence of typical seizures and video-EEG findings." | 2.74 | [Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children]. ( Chen, L; Hu, Y; Huang, TS; Li, B; Liao, JX; Zhu, JL, 2009) |
| "Lamotrigine was well tolerated in this study." | 2.73 | Lamotrigine monotherapy for newly diagnosed typical absence seizures in children. ( Frank, LM; Hammer, AE; Holmes, GL; Kerls, S; Messenheimer, J; Philbrook, B; Sheth, RD; Vuong, A; Wooten, JD, 2008) |
| "Lamotrigine has demonstrated efficacy from published randomized clinical trials for childhood partial seizures, absence seizures, and for the generalized seizures associated with Lennox-Gastaut syndrome." | 2.72 | Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures. ( Hammer, AE; Kerls, SP; Messenheimer, JA; Trevathan, E; Vuong, A, 2006) |
| "Lamotrigine (LTG) is an anti-epileptic drug effective in partial seizures and generalized epilepsy." | 2.69 | Lamotrigine in typical absence epilepsy. ( Buoni, S; Fois, A; Grosso, S, 1999) |
| " Dosing in generalized seizures is similar to that for partial seizures." | 2.40 | Lamotrigine in absence and primary generalized epilepsies. ( Holmes, GL; Mikati, MA, 1997) |
| "Vigabatrin is a specific and irreversible inhibitor of the enzyme gamma-amino-butyric-acid (GABA) transferase." | 2.39 | [Vigabatrin and lamotrigin: experiences with 2 new anticonvulsants in the Swiss epilepsy clinic]. ( Krämer, G; Vogt, H, 1995) |
| "Levetiracetam was preferred as an add-on therapy for both generalized and focal epilepsy." | 1.56 | Treatment of epilepsy in adults: Expert opinion in South Korea. ( Byun, JI; Cho, YW; Kang, KW; Kim, D; Kim, DW; Kim, JM; Kim, KT; Lee, ST; No, YJ; Seo, JG; Yang, KI, 2020) |
| "Childhood absence epilepsy is a common generalized epilepsy syndrome characterized by childhood onset of frequent sporadic absence seizures." | 1.51 | Case of Childhood Absence Epilepsy with Focal Spikes. ( Lu, HJ; Shi, MT; Yu, YL, 2019) |
| " The initial dosage of lamotrigine was 6." | 1.43 | Lamotrigine monotherapy for paroxysmal kinesigenic dyskinesia in children. ( Hu, Y; Li, F; Li, W; Lin, ZD; Poonit, ND; Xue, CC, 2016) |
| "This is a case report of an adult with childhood absence epilepsy whose daily absence seizures ceased with adjunctive ezogabine." | 1.40 | Ezogabine treatment of childhood absence epilepsy. ( Vossler, DG; Yilmaz, U, 2014) |
| "This showed a periventricular nodular heterotopia in the mid to anterior horn of the right lateral ventricle." | 1.36 | Absence epilepsy and periventricular nodular heterotopia. ( Arts, WF; Brooks, A; de Coo, IF; de Wit, MC; Lequin, MH; Mancini, GM; Schippers, HM; Visser, GH, 2010) |
| "The syndrome is characterized by mental impairment, frequent seizures of multiple types that are particularly resistant to treatment, and high rates of seizure-related injury." | 1.36 | The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK. ( Benedict, A; Maclaine, G; Verdian, L, 2010) |
| "Valproic acid is an effective anti-epileptic medication often used for long-term control of seizure disorders that has been implicated in hematological toxicities, including rare reports of myelodysplasia and acute leukemia." | 1.35 | Translocation-positive acute myeloid leukemia associated with valproic acid therapy. ( Ben-Ezra, J; Massey, GV; Riley, RS; Russell, EC; Williams, DC, 2008) |
| "A 25-year-old girl with mild mental retardation had a 6-year history of absence seizures, with occasional head drop." | 1.31 | Mild generalized epilepsy and developmental disorder associated with large inv dup(15). ( Canevini, MP; Canger, R; Cavani, S; Chifari, R; Elia, M; Guerrini, R; Pierluigi, M; Sgrò, V, 2002) |
| " Seizures became diurnal and frequent, not modified by carbamazepine (CBZ) or valproate (VPA) but responding to VPA and lamotrigine (LTG) with recommended dosage schedules for this combination." | 1.30 | Paradoxic reaction to lamotrigine in a child with benign focal epilepsy of childhood with centrotemporal spikes. ( Boyd, S; Catania, S; Cross, H; de Sousa, C, 1999) |
| "In 15 patients with juvenile myoclonic epilepsy, complete seizure control was achieved in 7 patients, in 6 patients myoclonia persisted." | 1.30 | Efficacy of lamotrigine in idiopathic generalized epilepsy syndromes: a video-EEG-controlled, open study. ( de Saint-Martin, A; Gericke, CA; Hirsch, E; Marescaux, C; Picard, F; Strumia, S, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (21.43) | 18.2507 |
| 2000's | 28 (40.00) | 29.6817 |
| 2010's | 24 (34.29) | 24.3611 |
| 2020's | 3 (4.29) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, J | 1 |
| Lin, XX | 1 |
| Ma, XM | 1 |
| Liu, H | 2 |
| Byun, JI | 1 |
| Kim, DW | 1 |
| Kim, KT | 1 |
| Yang, KI | 1 |
| Lee, ST | 1 |
| Seo, JG | 1 |
| No, YJ | 1 |
| Kang, KW | 1 |
| Kim, D | 1 |
| Kim, JM | 1 |
| Cho, YW | 1 |
| Brigo, F | 3 |
| Igwe, SC | 3 |
| Lattanzi, S | 2 |
| Shinnar, RC | 1 |
| Shinnar, S | 3 |
| Cnaan, A | 3 |
| Clark, P | 1 |
| Dlugos, D | 3 |
| Hirtz, DG | 3 |
| Hu, F | 1 |
| Liu, C | 1 |
| Masur, D | 3 |
| Weiss, EF | 1 |
| Glauser, TA | 4 |
| Rosati, A | 1 |
| Ilvento, L | 1 |
| Lucenteforte, E | 1 |
| Pugi, A | 1 |
| Crescioli, G | 1 |
| McGreevy, KS | 1 |
| Virgili, G | 1 |
| Mugelli, A | 1 |
| De Masi, S | 1 |
| Guerrini, R | 3 |
| Yasumoto, S | 2 |
| Ohtsuka, Y | 1 |
| Sato, K | 2 |
| Kurata, A | 2 |
| Numachi, Y | 2 |
| Shimizu, M | 2 |
| Miao, A | 1 |
| Wang, Y | 2 |
| Xiang, J | 1 |
| Liu, Q | 1 |
| Chen, Q | 1 |
| Qiu, W | 1 |
| Tang, L | 1 |
| Gao, Y | 1 |
| Wu, C | 1 |
| Yu, Y | 1 |
| Sun, J | 1 |
| Jiang, W | 1 |
| Shi, Q | 1 |
| Zhang, T | 1 |
| Hu, Z | 1 |
| Wang, X | 1 |
| Kessler, SK | 1 |
| McGinnis, E | 1 |
| Yu, YL | 1 |
| Shi, MT | 1 |
| Lu, HJ | 1 |
| Vossler, DG | 1 |
| Yilmaz, U | 1 |
| Mamalyga, ML | 1 |
| Li, F | 1 |
| Lin, ZD | 1 |
| Hu, Y | 2 |
| Li, W | 1 |
| Xue, CC | 1 |
| Poonit, ND | 1 |
| Holmes, GL | 3 |
| Frank, LM | 2 |
| Sheth, RD | 1 |
| Philbrook, B | 1 |
| Wooten, JD | 1 |
| Vuong, A | 2 |
| Kerls, S | 1 |
| Hammer, AE | 2 |
| Messenheimer, J | 1 |
| Huang, TS | 1 |
| Zhu, JL | 1 |
| Li, B | 1 |
| Chen, L | 1 |
| Liao, JX | 1 |
| Penovich, PE | 1 |
| Willmore, LJ | 1 |
| Benedict, A | 1 |
| Verdian, L | 1 |
| Maclaine, G | 1 |
| Clark, PO | 2 |
| Capparelli, EV | 1 |
| Adamson, PC | 2 |
| Vining, EP | 1 |
| Potera, C | 1 |
| de Wit, MC | 1 |
| Schippers, HM | 1 |
| de Coo, IF | 1 |
| Arts, WF | 1 |
| Lequin, MH | 1 |
| Brooks, A | 1 |
| Visser, GH | 1 |
| Mancini, GM | 1 |
| Veerapandiyan, A | 1 |
| Gallentine, WB | 1 |
| Winchester, SA | 1 |
| Baker, J | 1 |
| Kansagra, SM | 1 |
| Mikati, MA | 2 |
| Hwang, H | 1 |
| Kim, H | 1 |
| Kim, SH | 2 |
| Lim, BC | 1 |
| Chae, JH | 1 |
| Choi, JE | 1 |
| Kim, KJ | 1 |
| Hwang, YS | 1 |
| Farooque, P | 1 |
| Goraya, J | 1 |
| Valencia, I | 1 |
| Carvalho, KS | 1 |
| Hardison, HH | 1 |
| Legido, A | 1 |
| Khurana, DS | 1 |
| Yeom, JS | 1 |
| Park, JS | 1 |
| Seo, JH | 1 |
| Park, ES | 1 |
| Lim, JY | 1 |
| Park, CH | 1 |
| Woo, HO | 1 |
| Youn, HS | 1 |
| Kang, HC | 1 |
| Hu, Q | 1 |
| Liu, XY | 1 |
| Xu, F | 1 |
| Li, X | 1 |
| Liu, ZG | 1 |
| Zeng, Z | 1 |
| Wang, M | 1 |
| Zhu, SQ | 1 |
| Huang, HY | 1 |
| Lee, HW | 1 |
| Chen, SD | 1 |
| Shaw, FZ | 1 |
| Chifari, R | 1 |
| Pierluigi, M | 1 |
| Cavani, S | 1 |
| Sgrò, V | 1 |
| Elia, M | 1 |
| Canger, R | 1 |
| Canevini, MP | 1 |
| Posner, E | 4 |
| Burneo, JG | 2 |
| Limdi, N | 1 |
| Kuzniecky, RI | 1 |
| Knowlton, RC | 1 |
| Mendez, M | 1 |
| Lawn, N | 1 |
| Faught, E | 1 |
| Welty, TE | 1 |
| Prasad, A | 2 |
| Posner, EB | 3 |
| Mohamed, K | 3 |
| Marson, AG | 3 |
| Das, KB | 1 |
| Harris, C | 1 |
| Smyth, DP | 1 |
| Cross, JH | 1 |
| McDonald, MA | 1 |
| Favilla, I | 1 |
| Coppola, G | 2 |
| Licciardi, F | 1 |
| Sciscio, N | 1 |
| Russo, F | 1 |
| Carotenuto, M | 2 |
| Pascotto, A | 2 |
| French, JA | 1 |
| Kanner, AM | 1 |
| Bautista, J | 1 |
| Abou-Khalil, B | 1 |
| Browne, T | 1 |
| Harden, CL | 1 |
| Theodore, WH | 1 |
| Bazil, C | 1 |
| Stern, J | 1 |
| Schachter, SC | 1 |
| Bergen, D | 1 |
| Hirtz, D | 1 |
| Montouris, GD | 1 |
| Nespeca, M | 1 |
| Gidal, B | 1 |
| Marks, WJ | 1 |
| Turk, WR | 1 |
| Fischer, JH | 1 |
| Bourgeois, B | 1 |
| Wilner, A | 1 |
| Faught, RE | 1 |
| Sachdeo, RC | 1 |
| Beydoun, A | 1 |
| Auricchio, G | 1 |
| Federico, R | 1 |
| Pedersen, AM | 1 |
| Rasmussen, NH | 1 |
| Miller, S | 1 |
| Bebin, EM | 1 |
| Schneider, G | 1 |
| Nabavi, D | 1 |
| Heuft, G | 1 |
| Trevathan, E | 1 |
| Kerls, SP | 1 |
| Messenheimer, JA | 1 |
| Hasan, M | 1 |
| Lerman-Sagie, T | 1 |
| Lev, D | 1 |
| Watemberg, N | 1 |
| Gélisse, P | 1 |
| Crespel, A | 1 |
| Williams, DC | 1 |
| Massey, GV | 1 |
| Russell, EC | 1 |
| Riley, RS | 1 |
| Ben-Ezra, J | 1 |
| Solovykh, NN | 1 |
| Korotkov, AG | 1 |
| Vogt, H | 1 |
| Krämer, G | 1 |
| Appleton, RE | 1 |
| Panayiotopoulos, CP | 2 |
| Ferrie, CD | 1 |
| Knott, C | 1 |
| Robinson, RO | 1 |
| Manonmani, V | 1 |
| Wallace, SJ | 1 |
| Buchanan, N | 1 |
| Hosford, DA | 1 |
| Clemens, B | 1 |
| Enlow, T | 1 |
| Manasco, P | 1 |
| Concannon, S | 1 |
| Chen, C | 1 |
| Womble, G | 1 |
| Casale, EJ | 1 |
| Buoni, S | 1 |
| Grosso, S | 1 |
| Fois, A | 1 |
| Belmonte, A | 1 |
| Parmeggiani, L | 1 |
| Perucca, E | 1 |
| Catania, S | 1 |
| Cross, H | 1 |
| de Sousa, C | 1 |
| Boyd, S | 1 |
| Echaniz-Laguna, A | 1 |
| Thiriaux, A | 1 |
| Ruolt-Olivesi, I | 1 |
| Marescaux, C | 2 |
| Hirsch, E | 2 |
| Gericke, CA | 1 |
| Picard, F | 1 |
| de Saint-Martin, A | 1 |
| Strumia, S | 1 |
| Guye, M | 1 |
| Bartolomei, F | 1 |
| Gastaut, JL | 1 |
| Chauvel, P | 1 |
| Dravet, C | 1 |
| Battaglia, D | 1 |
| Iuvone, L | 1 |
| Stefanini, MC | 1 |
| Acquafondata, C | 1 |
| Lettori, D | 1 |
| Chiricozzi, F | 1 |
| Pane, M | 1 |
| Mittica, A | 1 |
| Guzzetta, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study[NCT00088452] | Phase 3 | 453 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| Localizing Functional Brain Cortices and Epileptogenic Zones With High Frequency Brain Signals[NCT00600717] | 420 participants (Anticipated) | Observational | 2000-11-01 | Enrolling by invitation | |||
| A Multi-center, Uncontrolled, Open-label, Evaluation of Lamotrigine Monotherapy on Newly Diagnosed Typical Absence Seizures in Children and Adolescents[NCT01431976] | Phase 3 | 20 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Evaluation of Lamotrigine in Subjects With Absence Seizures[NCT00144872] | Phase 1 | 54 participants (Actual) | Interventional | 2004-11-01 | Completed | ||
| Phase 3: Metabolism of Lamotrigine During Treatment With Oral Contraceptives[NCT00266149] | Phase 3 | 10 participants | Interventional | 2003-06-30 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A Confidence Index of 0.60 or higher on the Conners' Continuous Performance Test at the visit at 16 or 20 weeks or at an earlier visit when treatment was discontinued (as long as the discontinuation occurred 1 month or more after the baseline visit and was not due to intolerable adverse events). A Confidence Index of 0.60 corresponds to a 60% probability that the child has clinical attention deficit disorder. (NCT00088452)
Timeframe: First 16-20 weeks of double blind therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Ethosuximide | 35 |
| Lamotrigine | 25 |
| Valproic Acid | 52 |
Treatment failure was defined as persistence of absence seizures at 12 months of double blind therapy, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician. (NCT00088452)
Timeframe: First 12 months of double blind therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Ethosuximide | 70 |
| Lamotrigine | 31 |
| Valproic Acid | 64 |
Treatment failure was defined as persistence of absence seizures at week 16 or week 20, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician. (NCT00088452)
Timeframe: First 16-20 weeks of double blind therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Ethosuximide | 81 |
| Lamotrigine | 43 |
| Valproic Acid | 85 |
Participants were asked to record the seizure codes, seizure duration, and their physical condition in a diary provided. (NCT01431976)
Timeframe: Extension Week 12 (Extension Visit 1 [Ext-V1], every 12 week after Ext-V1 and until withdrawal
| Intervention | Days (Mean) |
|---|---|
| Lamotrigine | 0.03 |
EEG is a diagnostic test for epilepsy. The EEG machine records the brain's electrical activity as a series of waveforms. HV is an activation technique used to provoke seizures during an EEG recording. An approximately 30-minute EEG with HV was performed on participants in a supine position. In the HV test, participants breathed through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute ) for 4 continuous minutes using a pin-wheel provided to them. (NCT01431976)
Timeframe: Up to Study Week 49
| Intervention | Participants (Number) |
|---|---|
| Lamotrigine | 8 |
EEG is a diagnostic test for epilepsy. The EEG machine records the brain's electrical activity as a series of waveforms. HV is an activation technique used to provoke seizures during an EEG recording. An approximately 30-minute EEG with HV was performed on participants in a supine position. In the HV test, participants breathed through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute) for 4 continuous minutes using a pin-wheel provided to them. (NCT01431976)
Timeframe: Week 12 of the Maintenance Phase (up to Study Week 50)
| Intervention | Participants (Number) |
|---|---|
| Lamotrigine | 7 |
Participants were asked to record the seizure codes, seizure duration, and their physical condition in a diary provided. Only participants data available at the analysis time point were analyzed (represented as n=X, X, X in category title) (NCT01431976)
Timeframe: Up to Study Week 50
| Intervention | Days (Mean) | |||
|---|---|---|---|---|
| Fixed Escalation Phase, n=20 | Escalation Phase, n=17 | Maintenance Phase, n=8 | FEP+EP+MP, n=20 | |
| Lamotrigine | 4.93 | 2.60 | 0.06 | 2.98 |
HV is an activation technique used to provoke seizures. Participants were instructed to breathe through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute) for 4 continuous minutes while sitting using a pin-wheel and were observed for clinical signs of seizures like impairment of consciousness; staring; eye enrollment; eye blinking; chewing movements; hand movement; other automatisms; atonic, tonic, clonic components; autonomic components; or any other signs. During the ExP, HV-clinical signs were assessed to confirm a status of seizure free. Only participants data available at the analysis time point were analyzed (represented as n=X, X, X in category title). (NCT01431976)
Timeframe: Extension Week 24 (Extension Visit 2 [Ext-V2], every 24 weeks after the Ext-V2 and until withdrawal
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Extension Week 24, n=7 | Extension Week 48, n=7 | Extension Week 72, n=7 | Extension Week 96, n=6 | Extension Week 120, n=6 | Extension Week 144, n=4 | Extension Week 168, n=1 | |
| Lamotrigine | 5 | 6 | 5 | 6 | 5 | 2 | 1 |
HV is an activation technique used to provoke seizures. Participants were instructed to breathe through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute) for 4 continuous minutes while sitting using a pin-wheel and were observed for clinical signs of seizures like impairment of consciousness; staring; eye enrollment; eye blinking; chewing movements; hand movement; other automatisms; atonic, tonic, clonic components; autonomic components; or any other signs. During the Escalation Phase, HV-clinical signs were assessed to confirm a status of seizure free. Only participants data available at the analysis time point were analyzed (represented as n=X, X, X in category title). (NCT01431976)
Timeframe: Up to Study Week 49
| Intervention | Participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.6 mg/kg, n=17 | 1.2 mg/kg, n=17 | 1.8 mg/kg, n=16 | 2.4 mg/kg, n=16 | 3.0 mg/kg, n=16 | 3.6 mg/kg, n=15 | 4.2 mg/kg, n=15 | 4.8 mg/kg, n=14 | 5.4 mg/kg, n=14 | 6.0 mg/kg, n=11 | 6.6 mg/kg, n=11 | 7.2 mg/kg, n=9 | 7.8 mg/kg, n=9 | 8.4 mg/kg, n=6 | 9.0 mg/kg, n=6 | 9.6 mg/kg, n=1 | |
| Lamotrigine | 1 | 1 | 2 | 2 | 2 | 1 | 0 | 4 | 1 | 1 | 0 | 3 | 0 | 2 | 1 | 1 |
HV is an activation technique used to provoke seizures. Participants were instructed to breathe through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute) for 4 continuous minutes while sitting using a pin-wheel and were observed for clinical signs of seizures like impairment of consciousness; staring; eye enrollment; eye blinking; chewing movements; hand movement; other automatisms; atonic, tonic, clonic components; autonomic components; or any other signs. During the Maintenace Phase, HV-clinical signs were assessed at Visit 1 (Week 4) and Visit 2 (Week 4). (NCT01431976)
Timeframe: Week 4 and Week 8 of the Maintenance Phase (up to Study Weeks 42 and 46, respectively)
| Intervention | Participants (Number) | |
|---|---|---|
| Week 4 | Week 8 | |
| Lamotrigine | 7 | 7 |
EEG is a diagnostic test for epilepsy. The EEG machine records the brain's electrical activity as a series of waveforms. HV is an activation technique used to provoke seizures during an EEG recording. An approximately 30-minute EEG with HV was performed on participants in a supine position. In the HV test, participants breathed through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute ) for 4 continuous minutes using a pin-wheel provided to them. Only participants data available at the analysis time point were analyzed (represented as n=X, X, X in category title). (NCT01431976)
Timeframe: Extension Week 12 (Extension Visit 1 [Ext-V1]), every 24 weeks after Ext-V1 and until withdrawal
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Extension Week 12, n=7 | Extension Week 36, n=7 | Extension Week 60, n=7 | Extension Week 84, n=6 | Extension Week 108, n=6 | Extension Week 132, n=6 | Extension Week 156, n=2 | |
| Lamotrigine | 6 | 5 | 6 | 6 | 6 | 6 | 2 |
17 reviews available for lamotrigine and Absence Seizure Disorder
| Article | Year |
|---|---|
The efficacy and safety of lamotrigine for absence seizures in children and adolescents: A systematic review and meta-analysis.
Topics: Adolescent; Anticonvulsants; Child; Epilepsy, Absence; Female; Humans; Lamotrigine; Male; Seizures | 2020 |
Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents.
Topics: Adolescent; Anticonvulsants; Child; Epilepsy, Absence; Ethosuximide; Female; Humans; Lamotrigine; Ma | 2021 |
Comparative efficacy of antiepileptic drugs in children and adolescents: A network meta-analysis.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Carbamazepine; Ch | 2018 |
A Practical Guide to Treatment of Childhood Absence Epilepsy.
Topics: Anticonvulsants; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Electroen | 2019 |
Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents.
Topics: Adolescent; Anticonvulsants; Child; Epilepsy, Absence; Ethosuximide; Humans; Lamotrigine; Randomized | 2019 |
Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents.
Topics: Adolescent; Anticonvulsants; Child; Epilepsy, Absence; Ethosuximide; Humans; Lamotrigine; Randomized | 2017 |
Absence seizures in children.
Topics: Acetates; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Epilepsy, Absence; Ethosuximi | 2002 |
Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents.
Topics: Adolescent; Anticonvulsants; Child; Epilepsy, Absence; Ethosuximide; Humans; Lamotrigine; Randomized | 2003 |
Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.
Topics: Acetates; Adolescent; Adult; Age Factors; Amines; Antipsychotic Agents; Carbamazepine; Child; Clinic | 2004 |
Absence seizures in children.
Topics: Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Epilepsy, Absence; Ethosuximide; Gabape | 2003 |
[Childhood and juvenile absence epilepsy. Treatment and prognosis].
Topics: Anticonvulsants; Child; Child Development; Child, Preschool; Cognition; Epilepsy, Absence; Ethosuxim | 2004 |
Absence seizures in children.
Topics: Adolescent; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Epilepsy, Absence; Ethosuxi | 2004 |
A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine.
Topics: Anticonvulsants; Child; Epilepsy, Absence; Ethosuximide; Humans; Lamotrigine; Randomized Controlled | 2005 |
Absence seizures in children.
Topics: Adolescent; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Epilepsy, | 2005 |
Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents.
Topics: Adolescent; Anticonvulsants; Child; Epilepsy, Absence; Ethosuximide; Humans; Lamotrigine; Randomized | 2005 |
[Vigabatrin and lamotrigin: experiences with 2 new anticonvulsants in the Swiss epilepsy clinic].
Topics: 4-Aminobutyrate Transaminase; Adult; Anticonvulsants; Child; Drug Therapy, Combination; Epilepsies, | 1995 |
Lamotrigine in absence and primary generalized epilepsies.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Epilepsy, Absence; Epilepsy, Generalize | 1997 |
12 trials available for lamotrigine and Absence Seizure Disorder
| Article | Year |
|---|---|
Pretreatment behavior and subsequent medication effects in childhood absence epilepsy.
Topics: Adolescent; Anticonvulsants; Checklist; Child; Child Behavior Disorders; Child, Preschool; Cross-Ove | 2017 |
Long-term efficacy and safety of lamotrigine monotherapy in Japanese and South Korean pediatric patients with newly diagnosed typical absence seizures: An open-label extension study.
Topics: Anticonvulsants; Brain; Child; Child, Preschool; Electroencephalography; Epilepsy, Absence; Female; | 2018 |
Lamotrigine monotherapy for newly diagnosed typical absence seizures in children: A multi-center, uncontrolled, open-label study.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsy, Absence; Fem | 2016 |
Lamotrigine monotherapy for newly diagnosed typical absence seizures in children.
Topics: Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsy, Absence; Female; Headach | 2008 |
[Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children].
Topics: Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsy, Absence; Female; Humans; | 2009 |
Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy.
Topics: Adolescent; Analysis of Variance; Anticonvulsants; Attention Deficit and Disruptive Behavior Disorde | 2010 |
[Efficacy and safety of the combined therapy of valproic acid and lamotrigine for epileptics].
Topics: Child; Child, Preschool; Drug Therapy, Combination; Epilepsies, Partial; Epilepsy; Epilepsy, Absence | 2012 |
Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months.
Topics: Age Factors; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blin | 2013 |
Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Disease-Free Survival; Drug Administration Sch | 2004 |
Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Double-Blind Method; Drug Administratio | 2006 |
Lamictal (lamotrigine) monotherapy for typical absence seizures in children.
Topics: Adolescent; Age Factors; Anticonvulsants; Body Height; Body Weight; Child; Child, Preschool; Dose-Re | 1999 |
Lamotrigine in typical absence epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Clonazepam; Drug Resistance; Electroencephalog | 1999 |
41 other studies available for lamotrigine and Absence Seizure Disorder
| Article | Year |
|---|---|
Treatment of epilepsy in adults: Expert opinion in South Korea.
Topics: Adult; Aged; Anticonvulsants; Epilepsies, Partial; Epilepsy, Absence; Epilepsy, Generalized; Expert | 2020 |
Ictal Source Locations and Cortico-Thalamic Connectivity in Childhood Absence Epilepsy: Associations with Treatment Response.
Topics: Anticonvulsants; Cerebral Cortex; Child; Child, Preschool; China; Epilepsy, Absence; Female; Gray Ma | 2019 |
Case of Childhood Absence Epilepsy with Focal Spikes.
Topics: Action Potentials; Anticonvulsants; Child; Drug Substitution; Electroencephalography; Epilepsy, Abse | 2019 |
Ezogabine treatment of childhood absence epilepsy.
Topics: Anticonvulsants; Carbamates; Drug Interactions; Electroencephalography; Epilepsy, Absence; Female; H | 2014 |
Effect of anticonvulsant therapy for absence epilepsy on heart function.
Topics: Animals; Anticonvulsants; Epilepsy, Absence; Heart; Lamotrigine; Male; Rats; Triazines | 2014 |
Lamotrigine monotherapy for paroxysmal kinesigenic dyskinesia in children.
Topics: Anticonvulsants; Child; Child, Preschool; Dystonia; Electroencephalography; Epilepsy, Absence; Femal | 2016 |
Use of a new antiepileptic drug or an old one as first drug for treatment of absence epilepsy.
Topics: Anticonvulsants; Drug Monitoring; Epilepsy, Absence; Ethosuximide; Humans; Lamotrigine; Treatment Ou | 2009 |
Lamotrigine and absence seizures: new indication. Try valproic acid first.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Approval; Epilepsy, Absence; Europe; Huma | 2009 |
The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Computer Simulation; Cost-Benefit Analy | 2010 |
Ethosuximide in childhood absence epilepsy--older and better.
Topics: Anticonvulsants; Child; Diagnosis, Differential; Epilepsy, Absence; Epilepsy, Tonic-Clonic; Ethosuxi | 2010 |
An older drug for childhood absence epilepsy.
Topics: Anticonvulsants; Child; Electroencephalography; Epilepsy, Absence; Ethosuximide; Humans; Lamotrigine | 2010 |
Absence epilepsy and periventricular nodular heterotopia.
Topics: Anticonvulsants; Child, Preschool; Drug Therapy, Combination; Electroencephalography; Epilepsy, Abse | 2010 |
Oculogyric crises secondary to lamotrigine overdosage.
Topics: Adult; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Overdose; Dr | 2011 |
Long-term effectiveness of ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsy, Absence; Eth | 2012 |
Early-onset childhood absence epilepsy: is it a distinct entity?
Topics: Age Factors; Age of Onset; Anticonvulsants; Child; Child Development; Child, Preschool; Cohort Studi | 2011 |
aPTT prolongation and skin eruption possibly associated with lamotrigine monotherapy in a paediatric patient.
Topics: Anticonvulsants; Blood Chemical Analysis; Blood Coagulation Factors; Child; Drug Eruptions; Electroe | 2011 |
Lamotrigine ameliorates seizures and psychiatric comorbidity in a rat model of spontaneous absence epilepsy.
Topics: Animals; Anticonvulsants; Anxiety Disorders; Comorbidity; Depressive Disorder; Disease Models, Anima | 2012 |
Mild generalized epilepsy and developmental disorder associated with large inv dup(15).
Topics: Adult; Age of Onset; Angelman Syndrome; Anticonvulsants; Chromosome Aberrations; Chromosome Inversio | 2002 |
Neurotoxicity following addition of intravenous valproate to lamotrigine therapy.
Topics: Administration, Oral; Adult; Ammonia; Anticonvulsants; Confusion; Drug Interactions; Drug Therapy, C | 2003 |
Unusual side effects of lamotrigine therapy.
Topics: Anticonvulsants; Child; Child Behavior Disorders; Chorea; Cognition Disorders; Epilepsy, Absence; Hu | 2003 |
Visual loss in a patient with lamotrigine-induced cicatrizing conjunctivitis.
Topics: Adult; Anticonvulsants; Cicatrix; Conjunctivitis, Allergic; Epilepsy, Absence; Female; Humans; Lamot | 2003 |
Lamotrigine as first-line drug in childhood absence epilepsy: a clinical and neurophysiological study.
Topics: Anticonvulsants; Child; Child, Preschool; Drug Administration Schedule; Electroencephalography; Epil | 2004 |
Video-EEG study in an adult and a child with eyelid myoclonia with absences.
Topics: Adult; Anticonvulsants; Child; Dominance, Cerebral; Drug Therapy, Combination; Electroencephalograph | 2004 |
Eye movement desensitization and reprocessing in the treatment of posttraumatic stress disorder in a patient with comorbid epilepsy.
Topics: Adult; Anticonvulsants; Comorbidity; Desensitization, Psychologic; Epilepsy, Absence; Eye Movements; | 2005 |
Recurrent absence status epilepticus (spike-and-wave stupor) associated with lamotrigine therapy.
Topics: Anticonvulsants; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Epilepsy, Ab | 2006 |
[Reintroduction of treatment with lamotrigine in combination with valproate after an initial allergic skin reaction].
Topics: Adult; Anticonvulsants; Drug Eruptions; Drug Therapy, Combination; Epilepsy, Absence; Female; Humans | 2006 |
Translocation-positive acute myeloid leukemia associated with valproic acid therapy.
Topics: Acute Disease; Anticonvulsants; Cell Differentiation; Cell Division; Child, Preschool; Chromosomes, | 2008 |
[The use of Lamiktal in treating epilepsy in children and adolescents].
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Chronic Disease; Drug Evaluation; Drug | 1994 |
Epilepsy with myoclonic absences.
Topics: Anticonvulsants; Epilepsy, Absence; Humans; Lamotrigine; Triazines | 1994 |
Interaction of lamotrigine with sodium valproate.
Topics: Adolescent; Anticonvulsants; Child; Drug Synergism; Epilepsy, Absence; Humans; Lamotrigine; Triazine | 1993 |
Epilepsy with myoclonic absences.
Topics: Anticonvulsants; Brain; Child; Child Behavior Disorders; Child, Preschool; Electroencephalography; E | 1994 |
Lamotrigine in the treatment of absence seizures.
Topics: Adolescent; Adult; Anticonvulsants; Child; Epilepsy, Absence; Female; Humans; Lamotrigine; Male; Tri | 1995 |
Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dru | 1997 |
Perioral myoclonia with absences? A case report with EEG and voltage mapping analysis.
Topics: Anticonvulsants; Brain Mapping; Child; Electroencephalography; Epilepsy, Absence; Female; Humans; La | 1997 |
Myoclonic status epilepticus following high-dosage lamotrigine therapy.
Topics: Anticonvulsants; Child; Electroencephalography; Epilepsies, Myoclonic; Epilepsy, Absence; Female; Hu | 1999 |
Paradoxic reaction to lamotrigine in a child with benign focal epilepsy of childhood with centrotemporal spikes.
Topics: Acute Disease; Anticonvulsants; Carbamazepine; Child; Electroencephalography; Epilepsy, Absence; Epi | 1999 |
Lupus anticoagulant induced by the combination of valproate and lamotrigine.
Topics: Antibodies, Anticardiolipin; Anticonvulsants; Child, Preschool; Dose-Response Relationship, Drug; Dr | 1999 |
Efficacy of lamotrigine (LTG) monotherapy.
Topics: Adolescent; Anticonvulsants; Child; Clinical Trials as Topic; Drug Administration Schedule; Electroe | 2000 |
Efficacy of lamotrigine in idiopathic generalized epilepsy syndromes: a video-EEG-controlled, open study.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug | 1999 |
Absence epilepsy with fast rhythmic discharges during sleep: an intermediary form of generalized epilepsy?
Topics: Adult; Age of Onset; Anticonvulsants; Cerebral Cortex; Child; Child, Preschool; Diagnosis, Different | 2001 |
Reversible aphasic disorder induced by lamotrigine in atypical benign childhood epilepsy.
Topics: Anticonvulsants; Aphasia; Child; Electroencephalography; Epilepsy, Absence; Female; Humans; Lamotrig | 2001 |